Share-based Payment Arrangement, Expense of Ventyx Biosciences, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Ventyx Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Ventyx Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $4,601,000, a 16% decline year-over-year.
  • Ventyx Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $19,373,000, a 19% decline year-over-year.
  • Ventyx Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $22,931,000, a 20% decline from 2023.
  • Ventyx Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $28,588,000, a 73% increase from 2022.
  • Ventyx Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $16,570,000, a 507% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Ventyx Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,373,000 $4,601,000 -$850,000 -16% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025 2025 Q3
Q2 2025 $20,223,000 $4,575,000 -$1,196,000 -21% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $21,419,000 $5,031,000 -$1,512,000 -23% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $22,931,000 $5,166,000 -$979,000 -16% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $23,910,000 $5,451,000 -$2,557,000 -32% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025 2025 Q3
Q2 2024 $26,467,000 $5,771,000 -$2,097,000 -27% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $28,564,000 $6,543,000 -$24,000 -0.36% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $28,588,000 $6,145,000 +$1,317,000 +27% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $27,271,000 $8,008,000 +$3,841,000 +92% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $23,430,000 $7,868,000 +$3,737,000 +90% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $19,693,000 $6,567,000 +$3,123,000 +91% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $16,570,000 $4,828,000 +$3,435,000 +247% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $13,135,000 $4,167,000 +$3,198,000 +330% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $9,937,000 $4,131,000 +$3,843,000 +1334% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $6,094,000 $3,444,000 +$3,364,000 +4205% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $2,730,000 $1,393,000 01 Oct 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
Q3 2021 $969,000 +$955,000 +6821% 01 Jul 2021 30 Sep 2021 10-Q 04 Nov 2022 2022 Q3
Q2 2021 $288,000 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $80,000 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q3 2020 $14,000 01 Jul 2020 30 Sep 2020 10-Q 18 Nov 2021 2021 Q3

Ventyx Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $22,931,000 -$5,657,000 -20% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $28,588,000 +$12,018,000 +73% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $16,570,000 +$13,840,000 +507% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
2021 $2,730,000 +$2,685,000 +5967% 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
2020 $45,000 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.